New study aims to reduce harmful side effects in rare cancer patients

NCT ID NCT07471425

Not yet recruiting Knowledge-focused Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow 1,100 people with advanced neuroendocrine tumors (a rare, slow-growing cancer) to see which treatments or treatment sequences cause the fewest long-term side effects. Researchers will track patients for up to 5 years, recording any side effects that last more than 6 months. The goal is to create a tool that helps doctors choose the best treatment plan for each patient, balancing effectiveness with quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE (NE) TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE (NE) TUMORS

Contacts and locations

Locations

APHM Marseille La Timone

Marseille, 13005, France
APHP Beaujon

Clichy, 92110, France
APHP Cochin

Paris, 75014, France
CHRU Tours

Tours, 37044, France
CHU Caen

Caen, 14000, France
CHU Clermont Ferrand

Clermont-Ferrand, 63000, France
CHU Dijon

Dijon, 21000, France
CHU Lille

Lille, 59000, France
CHU Poitiers

Poitiers, 86196, France
CHU Reims

Reims, 51092, France
CHU Strasbourg

Strasbourg, 67200, France
CHU Toulouse

Toulouse, 31300, France
Centre Eugene Maquis

Rennes, 35000, France
Hôpital Edouard Herriot

Lyon, 69003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.